GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » WACC %

Myomo (MYO) WACC % :16.43% (As of Dec. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Myomo WACC %?

As of today (2024-12-11), Myomo's weighted average cost of capital is 16.43%%. Myomo's ROIC % is -158.46% (calculated using TTM income statement data). Myomo earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Myomo WACC % Historical Data

The historical data trend for Myomo's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myomo WACC % Chart

Myomo Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
WACC %
Get a 7-Day Free Trial 8.03 12.35 8.74 8.57 13.01

Myomo Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.04 13.01 13.13 13.74 13.60

Competitive Comparison of Myomo's WACC %

For the Medical Devices subindustry, Myomo's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo's WACC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's WACC % distribution charts can be found below:

* The bar in red indicates where Myomo's WACC % falls into.



Myomo WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Myomo's market capitalization (E) is $214.980 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2024, Myomo's latest one-year quarterly average Book Value of Debt (D) is $0.479 Mil.
a) weight of equity = E / (E + D) = 214.980 / (214.980 + 0.479) = 0.9978
b) weight of debt = D / (E + D) = 0.479 / (214.980 + 0.479) = 0.0022

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.287%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Myomo's beta is 2.03.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.287% + 2.03 * 6% = 16.467%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2024, Myomo's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $0.479 Mil.
Cost of Debt = -0 / 0.479 = 0%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.352 / -8.032 = -4.38%, which is less than 0%. Therefore it's set to 0%.

Myomo's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9978*16.467%+0.0022*0%*(1 - 0%)
=16.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myomo  (AMEX:MYO) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Myomo's weighted average cost of capital is 16.43%%. Myomo's ROIC % is -158.46% (calculated using TTM income statement data). Myomo earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Myomo Business Description

Traded in Other Exchanges
Address
137 Portland Street, 4th Floor, Boston, MA, USA, 02114
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Executives
Harry Kovelman officer: Chief Medical Officer C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Thomas F Kirk director
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis director, officer: Chief Executive Officer 9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry officer: Chief Financial Officer
Yitzchak Jacobovitz director MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell officer: Chief Commercial Officer C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr. director 19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton officer: Chief Marketing Officer 53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft officer: VP, General Manager C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green officer: Chief Medical Officer C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser officer: Chief Financial Officer BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn officer: VP, Sales C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi director 2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp director 75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042

Myomo Headlines

From GuruFocus

Q1 2023 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2024 Myomo Inc Earnings Call Transcript

By GuruFocus Research 05-10-2024

Q4 2022 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2021 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2024 Myomo Inc Earnings Call Transcript

By GuruFocus News 11-07-2024

Q3 2022 Myomo Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024